In this episode of Post-Scrip, Henry introduces Jeanne M. Brennan, BS Pharm, JD, and, William J. Stilling, BS Pharm, MS, JD.  They discuss the upcoming Semaglutide as a Case Study for Compounding Legal Issues and Barriers Semaglutide provides a case study for pharmacists who are trying to meet patient and prescriber needs and who strive to comply with federal and state laws and the explosive demand for semaglutide has created opportunities and risks. This demand has created a nationwide shortage of Ozempic and Wegovy. State boards of pharmacy are responding to complaints against pharmacists who are compounding semaglutide. Obesity has been a national health epidemic for years. There is an insatiable hunger for weight loss solutions. Americans want to lose weight. Semaglutide appears to be the newest wonder weight loss drug. Patients and prescribers are touting its effectiveness on social media. The New England Journal of Medicine published a study in 2021 that has provided credibility to the weight loss industry. There are also the STEP trials providing dosing guidelines for weight loss. Join us at the 34th annual conference:  Developments in Pharmacy Law Seminar , November 2-5, 2023 in San Antonio, Texas